<DOC>
	<DOC>NCT01062061</DOC>
	<brief_summary>This survey is conducted for preparing application materials for re-examination under the Korean Pharmaceutical Affairs Laws and its Enforcement Regulation; its aim is to reconfirm the clinical usefulness of VARIVAX through collecting the safety information according to the Re-examination Regulation for New Drugs.</brief_summary>
	<brief_title>Re-examination Study For Varivax (V210-059 AM2)</brief_title>
	<detailed_description>This post-marketing survey was conducted in the usual routine practice and the investigator enrolled participants vaccinated with VARIVAX continuously after study start. The purpose of the study was to assess the occurrence of adverse events and to identify factors that may affect the safety of the vaccine under real-life, post-marketing conditions. No hypothesis testing was conducted in this survey.</detailed_description>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<criteria>Participants must be vaccinated with VARIVAX as a standard of care Participants who have been previously vaccinated with VARIVAX Contraindication with VARIVAX</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Varicella</keyword>
</DOC>